Methylene Blue Reduces Electroretinogram Distortion and Ganglion Cell Death in a Rat Model of Glaucoma.

Glaucoma is the second leading cause of blindness worldwide and is, in most cases, a consequence of elevated intraocular pressure (IOP), ultimately resulting in the death of retinal ganglion cells (RGCs). Current treatments are mostly focused on normalizing IOP, but we propose the additional use of neuroprotective agents, including methylene blue (MB), to block the loss of RGCs. Wistar rats were subjected to episcleral vein cauterization (EVC) in the left eye while the right eye was sham-operated. One week later, they were divided into two groups, which were injected with either 2.0 mg/kg MB or phosphate-buffered saline (PBS), twice a day, for 7 days. Fifteen days after surgery, rats were tested with scotopic electroretinography (ERG) or pattern electroretinography (PERG). After sacrifice, the number of RGCs and the thickness of the inner retina (IR) were evaluated both in the peripheral and central areas of the retina. Scotopic ERG showed a marked reduction (p < 0.0001) on the a- and b-wave amplitude and oscillatory potential (OP) complexity of the eyes subjected to EVC. These parameters were significantly (p < 0.01) restored by the application of MB. PERG indicated that EVC was responsible for a very significant decrease in N2 amplitude (p < 0.0001) and prolongation of N2 implicit time (p < 0.0001). Treatment with MB significantly restored N2 amplitude (p < 0.0001). In parallel with the ERG results, morphological analysis showed a significant loss of RGCs (p < 0.0001) and IR thickness (p < 0.0001) in both the peripheral and central retinas subjected to EVC, which was significantly prevented (p < 0.0001) by MB treatment. We have shown that MB treatment can be effective in preventing physiological and morphological hallmarks of optic neuropathy in a model of ocular hypertension, which faithfully recapitulates human open-angle glaucoma. Due to its high safety profile, this drug could therefore represent a new pharmacologic strategy to prevent vision loss in glaucoma patients.

Contusión medular en ratas tratadas con hipotermia sistémica. Expresión de proteínas inducibles por frío experimental / Spinal cord contusion in rats treated with systemic hypothermia. Experimental cold-inducible protein expression

Introducción: La lesión traumática de la médula espinal es la principal causa mundial de discapacidad motora y una prioridad para la OMS. El objetivo de esta investigación fue estudiar el efecto de la hipotermia terapéutica tras una contusión medular. Materiales y Métodos: Se utilizaron ratas macho a las que se les generó una contusión medular. Se formaron cuatro grupos (6 animales por grupo): a) de control, b) con lesión en normotermia (24 °C, sacrificados 12 h después de la lesión, c) con lesión en normotermia (24 °C, sacrificados 24 h después de la lesión) y d) lesión en hipotermia (8 °C, durante 180 min, sacrificados 24 h después de la lesión). Se estudió la expresión de la CIRBP, la caspasa-3 y la Neu-N. Resultados: La lesión medular aumentó ligeramente la expresión de CIRBP a las 24 h y, de manera importante, la de caspasa-3, todo acompañado por imágenes de motoneuronas dañadas en el asta anterior. En los animales tratados con hipotermia, se observó una alta expresión de CIRBP y niveles muy bajos de caspasa-3, que no se distinguen de los controles. El número de motoneuronas viables se restauró parcialmente. Conclusiones: Este modelo experimental resultó eficaz para inducir una lesión medular, demostró la protección neuronal mediada por hipotermia. El aumento de la expresión de CIRBP en la médula espinal de ratas con lesión e hipotermia comparado con el del grupo normotérmico abre el camino para un posible uso de sustancias que incrementen la CIRBP como terapéutica para las lesiones medulares contusivas. Nivel de Evidencia: I

Introduction: Traumatic spinal cord injury is the leading cause of motor disability worldwide, and the WHO considers it a priority. This study sought to investigate the effects of therapeutic hypothermia following spinal cord contusion. Materials and Methods: Male rats that underwent experimental spinal cord contusion were used. For this purpose, four experimental groups were created (n=6 per group): a) control, b) lesion in normothermia (24°C, sacrificed 12h after the injury), c) lesion in normothermia (24°C, sacrificed 24h after the injury), and d) hypothermic injury (8°C for 180 min, sacrificed 24h after the injury). The expression of cold-inducible RNA-binding protein (CIRBP), Caspase-3, and NeuN was studied. Results: At 24 hours, spinal cord damage raised CIRBP expression slightly while also increasing Caspase-3 significantly. All of this was accompanied by images of damaged motor neurons in the anterior horn. In animals treated with hypothermia, high expression of CIRBP and very low levels of Caspase-3 were observed, which were indistinguishable from controls. Furthermore, the number of viable motor neurons was partially restored. Conclusions: The experimental model developed in this study was effective at inducing spinal cord injury, demonstrating neuronal protection through hypothermia. The increased expression of CIRBP in the spinal cord of rats with injury and hypothermic treatment when compared to the normothermic group suggests the possibility of using substances that increase CIRBP as therapies for the treatment of contusive spinal cord injuries. Level of Evidence: I

A hypothermia mimetic molecule (zr17-2) reduces ganglion cell death, gliosis, and electroretinogram distortion in male rats subjected to perinatal asphyxia.

Introduction: Perinatal asphyxia (PA) represents a major problem in perinatology and may cause visual losses, including blindness. We, and others, have shown that hypothermia prevents retinal symptoms associated to PA. In the present work, we evaluate whether a hypothermia mimetic small molecule, zr17-2, has similar effects in the context of PA. Methods: Four experimental groups were studied in male rats: Naturally born rats as controls (CTL), naturally born rats injected s.c. with 50 µL of 330 nmols/L zr17-2 (ZR), animals that were exposed to PA for 20 min at 37°C (PA), and rats that were exposed to PA and injected with zr17-2 (PA-ZR). Forty-five days after treatment, animals were subjected to electroretinography. In addition, morphological techniques (TUNEL, H&E, multiple immunofluorescence) were applied to the retinas. Results: A reduction in the amplitude of the a- and b-wave and oscillatory potentials (OP) of the electroretinogram (ERG) was detected in PA animals. Treatment with zr17-2 resulted in a significant amelioration of these parameters (p < 0.01). In PA animals, a large number of apoptotic cells was found in the GCL. This number was significantly reduced by treatment with the small molecule (p < 0.0001). In a similar way, the thickness of the inner retina and the intensity of GFAP immunoreactivity (gliosis) increased in PA retinas (p < 0.0001). These parameters were corrected by the administration of zr17-2 (p < 0.0001). Furthermore, injection of the small molecule in the absence of PA did not modify the ERG nor the morphological parameters studied, suggesting a lack of toxicity. Discussion: In conclusion, our results indicate that a single s.c. injection of zr17-2 in asphyctic neonates may provide a novel and efficacious method to prevent the visual sequelae of PA.

A hypothermia mimetic molecule (zr17-2) reduces ganglion cell death and electroretinogram distortion in a rat model of intraorbital optic nerve crush (IONC).

Introduction: Ocular and periocular traumatisms may result in loss of vision. Our previous work showed that therapeutic hypothermia prevents retinal damage caused by traumatic neuropathy. We also generated and characterized small molecules that elicit the beneficial effects of hypothermia at normal body temperature. Here we investigate whether one of these mimetic molecules, zr17-2, is able to preserve the function of eyes exposed to trauma. Methods: Intraorbital optic nerve crush (IONC) or sham manipulation was applied to Sprague-Dawley rats. One hour after surgery, 5.0 µl of 330 nmol/L zr17-2 or PBS, as vehicle, were injected in the vitreum of treated animals. Electroretinograms were performed 21 days after surgery and a- and b-wave amplitude, as well as oscillatory potentials (OP), were calculated. Some animals were sacrificed 6 days after surgery for TUNEL analysis. All animal experiments were approved by the local ethics board. Results: Our previous studies showed that zr17-2 does not cross the blood-ocular barrier, thus preventing systemic treatment. Here we show that intravitreal injection of zr17-2 results in a very significant prevention of retinal damage, providing preclinical support for its pharmacological use in ocular conditions. As previously reported, IONC resulted in a drastic reduction in the amplitude of the b-wave (p < 0.0001) and OPs (p < 0.05), a large decrease in the number of RGCs (p < 0.0001), and a large increase in the number of apoptotic cells in the GCL and the INL (p < 0.0001). Interestingly, injection of zr17-2 largely prevented all these parameters, in a very similar pattern to that elicited by therapeutic hypothermia. The small molecule was also able to reduce oxidative stress-induced retinal cell death in vitro. Discussion: In summary, we have shown that intravitreal injection of the hypothermia mimetic, zr17-2, significantly reduces the morphological and electrophysiological consequences of ocular traumatism and may represent a new treatment option for this cause of visual loss.